Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CCR6 | P51684 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4766625 | 0.82 | MEN1 (0.40) | MEN1KMT2AATMKDM4EALDH1A1 | |
| SCHEMBL72463 | 0.76 | MEN1 (0.36) | MEN1KMT2AATMKDM4EALDH1A1 | |
| SCHEMBL4263945 | 0.76 | MEN1 (0.36) | MEN1KMT2AATMKDM4EALDH1A1 | |
| SCHEMBL12846005 | 0.75 | — | — | |
| SCHEMBL8472169 | 0.74 | — | — | |
| SCHEMBL6059202 | 0.74 | MEN1 (0.42) | MEN1KMT2AATMKDM4EALDH1A1 | |
| SCHEMBL92834 | 0.72 | — | — | |
| SCHEMBL177491 | 0.72 | — | — | |
| SCHEMBL4602875 | 0.71 | FAAH (0.40) | — | |
| SCHEMBL23732974 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129410-B2 | Sleep maintenance insomnia; circadian rhythm abnormalities; side effect reduction | HYPNION, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8101596-B2 | Loxapine analogs and methods of use thereof | HYPNION INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-7807828-B2 | Olanzapine analogs and methods of use thereof | HYPNION, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20090186872-A1 | LOXAPINE ANALOGS AND METHODS OF USE THEREOF | EDGAR DALE M | 2009-07-23 | — | — | US | disclosed |
| US-7563785-B2 | Quetiapine analogs and methods of use thereof | HYPNION, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | HYPNION, INC. | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | GABRA5, GABRE, HCRTR2 | MEN1 4336/4885KMT2A 551/4885ATM 4562/4885 |
| US-20090186872-A1 | LOXAPINE ANALOGS AND METHODS OF USE THEREOF | HCRTR2, HCRTR1, HTR3B | MEN1 4531/4885KMT2A 318/4885ATM 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.